Foxm1b Transcription Factor is Essential for Development of Hepatocellular Carcinomas and is Negatively Regulated by the P19ARF Tumor Suppressor

Overview

Journal Genes Dev

Specialty Molecular Biology

Date 2004 Apr 15

PMID 15082532

Citations 201

Authors

Vladimir V Kalinichenko

Michael L Major

Xinhe Wang

Vladimir Petrovic

Joseph Kuechle

Helena M Yoder

Margaret B Dennewitz

Brian Shin

Abhishek Datta

Pradip Raychaudhuri

Robert H Costa

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide. Here, we provide evidence that the Forkhead Box (Fox) m1b (Foxm1b or Foxm1) transcription factor is essential for the development of HCC. Conditionally deleted Foxm1b mouse hepatocytes fail to proliferate and are highly resistant to developing HCC in response to a Diethylnitrosamine (DEN)/Phenobarbital (PB) liver tumor-induction protocol. The mechanism of resistance to HCC development is associated with nuclear accumulation of the cell cycle inhibitor p27(Kip1) protein and reduced expression of the Cdk1-activator Cdc25B phosphatase. We showed that the Foxm1b transcription factor is a novel inhibitory target of the p19(ARF) tumor suppressor. Furthermore, we demonstrated that conditional overexpression of Foxm1b protein in osteosarcoma U2OS cells greatly enhances anchorage-independent growth of cell colonies on soft agar. A p19(ARF) 26-44 peptide containing nine D-Arg to enhance cellular uptake of the peptide was sufficient to significantly reduce both Foxm1b transcriptional activity and Foxm1b-induced growth of U2OS cell colonies on soft agar. These results suggest that this (D-Arg)(9)-p19(ARF) 26-44 peptide is a potential therapeutic inhibitor of Foxm1b function during cellular transformation. Our studies demonstrate that the Foxm1b transcription factor is required for proliferative expansion during tumor progression and constitutes a potential new target for therapy of human HCC tumors.

Citing Articles

Malignant Transformation of Meningiomas.

Yu J, Deng J, Ren L, Hua L, Gong Y J Cancer. 2025; 16(5):1684-1693.

PMID: 39991581 PMC: 11843249. DOI: 10.7150/jca.105024.

The conformation of FOXM1 homodimers in vivo is crucial for regulating transcriptional activities.

Hsu C, Yao X, Chen S, Tsuo T, Wang I Nucleic Acids Res. 2024; 52(22):13625-13643.

PMID: 39535028 PMC: 11662942. DOI: 10.1093/nar/gkae988.

Lysyl Oxidase (LOX) Family Proteins: Key Players in Breast Cancer Occurrence and Progression.

Li J, Wang X, Liu R, Zi J, Li Y, Li Z J Cancer. 2024; 15(16):5230-5243.

PMID: 39247609 PMC: 11375560. DOI: 10.7150/jca.98688.

The Promise of Combination Therapies with FOXM1 Inhibitors for Cancer Treatment.

Merjaneh N, Hajjar M, Lan Y, Kalinichenko V, Kalin T Cancers (Basel). 2024; 16(4).

PMID: 38398147 PMC: 10886945. DOI: 10.3390/cancers16040756.

FOXM1, MEK, and CDK4/6: New Targets for Malignant Peripheral Nerve Sheath Tumor Therapy.

Voigt E, Quelle D Int J Mol Sci. 2023; 24(17).

PMID: 37686402 PMC: 10487994. DOI: 10.3390/ijms241713596.

References

POMERANTZ J, Schreiber-Agus N, Liegeois N, Silverman A, Alland L, Chin L . The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell. 1998; 92(6):713-23. DOI: 10.1016/s0092-8674(00)81400-2. View

Tamano S, Merlino G, Ward J . Rapid development of hepatic tumors in transforming growth factor alpha transgenic mice associated with increased cell proliferation in precancerous hepatocellular lesions initiated by N-nitrosodiethylamine and promoted by phenobarbital. Carcinogenesis. 1994; 15(9):1791-8. DOI: 10.1093/carcin/15.9.1791. View

Thorgeirsson S, Teramoto T, Factor V . Dysregulation of apoptosis in hepatocellular carcinoma. Semin Liver Dis. 1998; 18(2):115-22. DOI: 10.1055/s-2007-1007148. View

Datta A, Nag A, Raychaudhuri P . Differential regulation of E2F1, DP1, and the E2F1/DP1 complex by ARF. Mol Cell Biol. 2002; 22(24):8398-408. PMC: 139864. DOI: 10.1128/MCB.22.24.8398-8408.2002. View

Block T, Mehta A, Fimmel C, Jordan R . Molecular viral oncology of hepatocellular carcinoma. Oncogene. 2003; 22(33):5093-107. DOI: 10.1038/sj.onc.1206557. View

Trembley J, Ebbert J, Kren B, Steer C . Differential regulation of cyclin B1 RNA and protein expression during hepatocyte growth in vivo. Cell Growth Differ. 1996; 7(7):903-16. View

Korver W, Schilham M, Moerer P, van den Hoff M, Dam K, Lamers W . Uncoupling of S phase and mitosis in cardiomyocytes and hepatocytes lacking the winged-helix transcription factor Trident. Curr Biol. 1998; 8(24):1327-30. DOI: 10.1016/s0960-9822(07)00563-5. View

Ishida S, Huang E, Zuzan H, Spang R, Leone G, West M . Role for E2F in control of both DNA replication and mitotic functions as revealed from DNA microarray analysis. Mol Cell Biol. 2001; 21(14):4684-99. PMC: 87143. DOI: 10.1128/MCB.21.14.4684-4699.2001. View

Weihrauch M, Benick M, Lehner G, Wittekind M, Bader M, Wrbitzk R . High prevalence of K-ras-2 mutations in hepatocellular carcinomas in workers exposed to vinyl chloride. Int Arch Occup Environ Health. 2001; 74(6):405-10. DOI: 10.1007/s004200100244. View

10.

Chen H, Egan J, Chiu J . Regulation and activities of alpha-fetoprotein. Crit Rev Eukaryot Gene Expr. 1997; 7(1-2):11-41. DOI: 10.1615/critreveukargeneexpr.v7.i1-2.20. View

11.

Chang H, Li J, Vogt P . Domains of the qin protein required for oncogenic transformation. Oncogene. 1996; 13(2):441-4. View

12.

Pan H, Yin C, Dyson N, Harlow E, Yamasaki L, Van Dyke T . Key roles for E2F1 in signaling p53-dependent apoptosis and in cell division within developing tumors. Mol Cell. 1998; 2(3):283-92. DOI: 10.1016/s1097-2765(00)80273-7. View

13.

Kops G, Medema R, Glassford J, Essers M, Dijkers P, Coffer P . Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors. Mol Cell Biol. 2002; 22(7):2025-36. PMC: 133681. DOI: 10.1128/MCB.22.7.2025-2036.2002. View

14.

Barr F, Nauta L, Davis R, Schafer B, Nycum L, Biegel J . In vivo amplification of the PAX3-FKHR and PAX7-FKHR fusion genes in alveolar rhabdomyosarcoma. Hum Mol Genet. 1996; 5(1):15-21. DOI: 10.1093/hmg/5.1.15. View

15.

Alkarain A, Slingerland J . Deregulation of p27 by oncogenic signaling and its prognostic significance in breast cancer. Breast Cancer Res. 2003; 6(1):13-21. PMC: 314445. DOI: 10.1186/bcr722. View

16.

Sandgren E, Luetteke N, Qiu T, Palmiter R, Brinster R, Lee D . Transforming growth factor alpha dramatically enhances oncogene-induced carcinogenesis in transgenic mouse pancreas and liver. Mol Cell Biol. 1993; 13(1):320-30. PMC: 358911. DOI: 10.1128/mcb.13.1.320-330.1993. View

17.

Wang X, Hung N, Costa R . Earlier expression of the transcription factor HFH-11B diminishes induction of p21(CIP1/WAF1) levels and accelerates mouse hepatocyte entry into S-phase following carbon tetrachloride liver injury. Hepatology. 2001; 33(6):1404-14. DOI: 10.1053/jhep.2001.24666. View

18.

Sherr C, McCormick F . The RB and p53 pathways in cancer. Cancer Cell. 2002; 2(2):103-12. DOI: 10.1016/s1535-6108(02)00102-2. View

19.

McAllister S, Dowdy S . TAT-mediated protein transduction into mammalian cells. Methods. 2001; 24(3):247-56. DOI: 10.1006/meth.2001.1186. View

20.

Wu H, Wade M, Krall L, GRISHAM J, Xiong Y, Van Dyke T . Targeted in vivo expression of the cyclin-dependent kinase inhibitor p21 halts hepatocyte cell-cycle progression, postnatal liver development and regeneration. Genes Dev. 1996; 10(3):245-60. DOI: 10.1101/gad.10.3.245. View